Weill Cornell Medicine investigators have received a total of $3.5 million from the Patient-Centered Outcomes Research Institute (PCORI) to study the effectiveness of telehealth services during the COVID-19 pandemic, and to develop models that can aid in clinical decision making in the treatment of the virus.
Dr. Bishoy Faltas works to develop more effective therapies for bladder cancer, a disease that’s notoriously hard to treat—and historically under-studied
My wife thinks she got me sick, and I think I got her sick. She was serving on a grand jury—in a room with dozens of people who had sniffles and coughs—and one afternoon she called me and said she’d been sent home with a fever and didn’t feel well.
Weill Cornell Medicine’s Clinical and Translational Science Center (CTSC) has been awarded a grant from the National Institutes of Health for COVID-19 research.
LGBTQ individuals battling mental health issues often confront a double stigma: prejudice and discrimination based on their sexual orientation or gender identity, as well as the negative bias that is frequently associated with mental illness. On top of that, studies have shown that when LGBTQ patients do go for treatment, they frequently feel uncomfortable or inadequately cared for.
Physicians and public health researchers have long sounded the alarm about the high incidence of cardiovascular disease in economically disadvantaged urban neighborhoods compared with more affluent ones. But in recent years, another disturbing disparity has become increasingly evident: that residents of underserved areas are also diagnosed with cancer—and die of the disease—at disproportionate rates.
In early March, Dr. Shetal Shah, MD ’00, was in Albany along with other doctors to lobby for important regulations to protect children’s health. As president of New York State Chapter 2 of the American Academy of Pediatrics, Dr. Shah had been there many times before, including last summer as the state grappled with the largest measles outbreak in decades.
Medical students at Weill Cornell Medicine-Qatar (WCM-Q) have answered a call from the Ministry of Public Health (MOPH) for volunteers to help tackle the COVID-19 pandemic.
The National Institutes of Health National Heart Lung and Blood Institute has awarded Weill Cornell Medicine investigators $4.2 million to compare quality of life outcomes in patients undergoing two different types of coronary artery bypass graft (CABG) surgery.
Hematology and oncology specialist Dr. Jeffrey Laurence answers questions about the connection between blood clotting and other symptoms of severe COVID-19.
With COVID-19 limiting resources and presenting logistical challenges for elective treatments, Weill Cornell Medicine and NewYork-Presbyterian clinicians offer guidance on treating cancer in three recently published papers.
As the epicenter of the COVID-19 pandemic moves to Latin America and Africa, Weill Cornell Medicine faculty based in Haiti, a country hard hit by natural disasters and poverty, have developed lessons on what low-resourced countries can do to address and treat the outbreak on the ground.
When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.
In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.
A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Dr. Monika Safford, chief of the Division of General Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, finds that obesity is linked to more serious complications from COVID-19, including in younger people.
As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.
Although COVID-19 is a threat to everyone, people of color have been hit especially hard by the virus — what has been called a “pandemic within the pandemic.”
With the goal of advancing the fight against COVID-19, the Partners of Citadel and Citadel Securities have made a $2 million gift to Weill Cornell Medicine to develop new approaches to protect people from the disease and identify new cases of it.
